About Jeff DeFlavio
Form D filings for Affect Therapeutics from 2021 to 2023 list Jeff DeFlavio as director.
Jeff DeFlavio first appears on SEC filings in 2021.
Experience
This experience comes from SEC filings. The years are when the filings name Jeff DeFlavio in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Jeff DeFlavio works with at each company, as listed on that company's latest Form D.
Affect Therapeutics, Inc. · Form D, Jul 12, 2023
JR
Jeff Rinehart
Director
KR
Kevin Ryan
Director
SP
Stuart Peterson
Director
KM
Kristin Muhlner
Chief Executive Officer and director